Anbieter: Universitätsbuchhandlung Herta Hold GmbH, Berlin, Deutschland
2nd ed. 2018. XVI, 395 p. Hardcover. Einband bestoßen, daher Mängelexemplar gestempelt, sonst sehr guter Zustand. Imperfect copy due to slightly bumped cover, apart from this in very good condition. Stamped. Sprache: Englisch.
Zustand: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.
EUR 56,33
Anzahl: 4 verfügbar
In den WarenkorbZustand: New. pp. 464 66:B&W 7 x 10 in or 254 x 178 mm Perfect Bound on White w/Gloss Lam.
Anbieter: Romtrade Corp., STERLING HEIGHTS, MI, USA
Zustand: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.
Anbieter: Buchpark, Trebbin, Deutschland
Zustand: Sehr gut. Zustand: Sehr gut | Seiten: 445 | Sprache: Englisch | Produktart: Bücher | Keine Beschreibung verfügbar.
Anbieter: CSG Onlinebuch GMBH, Darmstadt, Deutschland
hard bound. Zustand: Sehr gut. Gebraucht - Sehr gut about this book: Written by a multidisciplinary team of experts involved in the development of standards and guidelines for its management in the USA, UK, Europe and Asia, the book contains succinct and knowledgeable summaries of the management of thyroid cancer. Every chapter describes a different aspect of care, and provides clear and detailed information about caring for patients with this group of tumors. The book follows the American and European model of treating thyroid cancer according to the high standards recommended by the available guidelines. This is an invaluable reference to health care professionals, from primary to tertiary care, involved in the management of thyroid cancer such as clinical nurse specialists, clinical psychologists, family medicine practitioners, specialists in palliative care (especially for anaplastic thyroid cancers), geneticists and surgeons, endocrinologists, oncologists, pathologists, and radiologists. Written for: Endocrinologists, oncologists, pathologists, radiologists, surgeons, clinical nurse specialists, clinical psychologists, family medicine practitioners, palliative care specialists, geneticists.
Anbieter: Ria Christie Collections, Uxbridge, Vereinigtes Königreich
EUR 162,61
Anzahl: Mehr als 20 verfügbar
In den WarenkorbZustand: New. In.
Anbieter: preigu, Osnabrück, Deutschland
Taschenbuch. Zustand: Neu. Practical Management of Thyroid Cancer | A Multidisciplinary Approach | Ujjal K. Mallick (u. a.) | Taschenbuch | xvi | Englisch | 2019 | Springer | EAN 9783030062859 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu.
Anbieter: preigu, Osnabrück, Deutschland
Taschenbuch. Zustand: Neu. Practical Management of Thyroid Cancer | A Multidisciplinary Approach | Ujjal K. Mallick (u. a.) | Taschenbuch | xvi | Englisch | 2025 | Springer | EAN 9783031386077 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu.
Sprache: Englisch
Verlag: Springer International Publishing, 2019
ISBN 10: 3030062856 ISBN 13: 9783030062859
Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland
Taschenbuch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - The new edition of this book highlights the recent advances and state-of-the art in surgical and non-surgical management of thyroid cancer. Readers will learn about the latest advances and recommendations in the field, from molecular studies and biomarkers to the changing epidemiology, kinase inhibition in drug discovery and new surgical approaches, such as intra-operative neural monitoring and robotics. The management of differentiated thyroid cancer as well as childhood cancer, survivorship and clinical trial design and findings and how these fit into cancer management are discussed in detail.This comprehensive volume provides an overview of the current world literature and outlines the practical aspects of management from world leaders in this field and helps clinicians and patients on practical matters. With a selection of authors from around the world it draws on international experience giving a global perspective to the topic. Following on from the success of the firstedition, it uses a multidisciplinary, evidence-based approach centered on the patient, discussing guidelines and how these have improved the quality of care and outcomes.This guide is aimed mainly at thyroidologists of all disciplines, (in training or experts) students, non-specialist clinicians, nursing staff, all the disciplines involved in a multidisciplinary team such as surgeons - Head & Neck or Endocrine and General Surgeons, Oncologists, Endocrinologists, Nuclear Medicine Physicians, Nuclear Medicine Physicists, Radiologists, Pathologists, Specialist Nurses, Geneticists, Clinical Psychologists, Palliative Care Physicians and, of course, patients.
Sprache: Englisch
Verlag: Springer International Publishing, Springer Nature Switzerland, 2025
ISBN 10: 3031386078 ISBN 13: 9783031386077
Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland
Taschenbuch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - Written by leading world experts, this third edition embraces the philosophy of international collaboration and disseminates the latest advances and transformative changes in the field of thyroid cancer.It provides a global health perspective, striving towards a uniform, equitable, evidence-based, cost-effective, practical, and patient-centred approach with high quality care crossing geographical boundaries. This book covers controversial issues and the most up-to-date management of differentiated, medullary, anaplastic, and rarer types of thyroid cancers together with survivorship issues and the lessons learnt during the Covid-19 Pandemic.The molecular landscape of thyroid cancers has a high frequency of oncogenic driver mutations and a high frequency of gene fusions treatable by new gene-specific systemic therapies. These include dual MAPK (Dabrafenib) / MEK (Trametinib) inhibition in BRAF V 600E mutated Anaplastic Thyroid Cancer, Larotrectinib, Entrectinib for NTRKgene fusion, Selpercartinib, Pralsetinib for RET fusion and mutations. These, newer and Master protocol trials, Tumour Agnostic drug development, Immune Checkpoint blockade and CAR-T therapy etc are discussed.The latest NICE and African Guidelines for Management are included. This would be of interest to readers as well.This book is aimed at thyroidologists of all disciplines, (in training or experts) students, non-specialist clinicians, nursing staff, all the disciplines involved in a multidisciplinary team such as surgeons - Head & Neck or Endocrine and General Surgeons, Oncologists, Endocrinologists, Nuclear Medicine Physicians, Nuclear Medicine Physicists, Radiologists, Pathologists, Specialist Nurses, Geneticists, Clinical Psychologists, Palliative Care Physicians and, in addition to AI in medicine, telemedicine experts, health policy makers, and scientists.
Sprache: Englisch
Verlag: Springer International Publishing, 2024
ISBN 10: 3031386043 ISBN 13: 9783031386046
Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland
Buch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - Written by leading world experts, this third edition embraces the philosophy of international collaboration and disseminates the latest advances and transformative changes in the field of thyroid cancer.It provides a global health perspective, striving towards a uniform, equitable, evidence-based, cost-effective, practical, and patient-centred approach with high quality care crossing geographical boundaries. This book covers controversial issues and the most up-to-date management of differentiated, medullary, anaplastic, and rarer types of thyroid cancers together with survivorship issues and the lessons learnt during the Covid-19 Pandemic.The molecular landscape of thyroid cancers has a high frequency of oncogenic driver mutations and a high frequency of gene fusions treatable by new gene-specific systemic therapies. These include dual MAPK (Dabrafenib) / MEK (Trametinib) inhibition in BRAF V 600E mutated Anaplastic Thyroid Cancer, Larotrectinib, Entrectinib for NTRKgene fusion, Selpercartinib, Pralsetinib for RET fusion and mutations. These, newer and Master protocol trials, Tumour Agnostic drug development, Immune Checkpoint blockade and CAR-T therapy etc are discussed.The latest NICE and African Guidelines for Management are included. This would be of interest to readers as well.This book is aimed at thyroidologists of all disciplines, (in training or experts) students, non-specialist clinicians, nursing staff, all the disciplines involved in a multidisciplinary team such as surgeons - Head & Neck or Endocrine and General Surgeons, Oncologists, Endocrinologists, Nuclear Medicine Physicians, Nuclear Medicine Physicists, Radiologists, Pathologists, Specialist Nurses, Geneticists, Clinical Psychologists, Palliative Care Physicians and, in addition to AI in medicine, telemedicine experts, health policy makers, and scientists.
Anbieter: Revaluation Books, Exeter, Vereinigtes Königreich
EUR 241,17
Anzahl: 2 verfügbar
In den WarenkorbHardcover. Zustand: Brand New. 1st edition. 445 pages. 10.00x7.25x1.00 inches. In Stock.
Sprache: Englisch
Verlag: Springer International Publishing, 2018
ISBN 10: 3319917242 ISBN 13: 9783319917245
Anbieter: Buchpark, Trebbin, Deutschland
Zustand: Hervorragend. Zustand: Hervorragend | Seiten: 416 | Sprache: Englisch | Produktart: Bücher | Keine Beschreibung verfügbar.